I was reading a fascinating piece in High Times this morning about the exploding market for MDMA gummies, DMT vape cartridges, mushroom chocolates, and a growing list of psychedelic products finding their way into smoke shops, websites, and social media feeds around the world. The article painted a picture that felt very familiar to anyone who has followed cannabis over the last twenty years.
Before dispensaries had polished counters and loyalty programs, cannabis lived in the gray market. People wanted access. Politicians moved slowly. Entrepreneurs moved fast.
Now, psychedelics seem to be following the same path.
According to the article, branded psychedelic products are showing up everywhere. Mushroom gummies are being sold overseas in retail kiosks. DMT vape products have reportedly become popular enough in parts of Southeast Asia that lawmakers there have pushed for broader vape restrictions. Social media platforms are flooded with trip reports, microdosing advice, and videos that normalize psychedelic use for millions of viewers. The market isn’t waiting for permission anymore. It’s already here.
And that’s where things get complicated.
On one hand, the renewed interest in psychedelics didn’t come out of nowhere. Studies involving psilocybin and MDMA have shown promise in treating conditions like PTSD, depression, and anxiety. For many people, these substances represent hope after years of failed treatments.
On the other hand, the products now popping up in the wild exist largely outside any meaningful regulatory framework.
That’s a problem.
When you buy a bag of gummies from a smoke shop that claims to contain “magic mushrooms,” what exactly are you getting? Is it psilocybin? A synthetic analog? Something entirely different? The average consumer has no way of knowing. The High Times article noted that independent testing has raised concerns about products containing compounds other than what appears on the label.
Cannabis veterans know this story all too well.
We’ve seen products mislabeled. We’ve watched regulators scramble to catch up with innovation. We’ve witnessed corporations swoop in once the risk had been absorbed by underground operators. We learned that if you don’t build sensible rules early, someone else eventually builds them for you—and not always in ways that benefit consumers.
The psychedelic movement now stands at a crossroads.
One road leads toward thoughtful regulation, product testing, consumer education, and respect for substances that many people consider both medicine and sacred tools for healing.
The other road leads toward flashy packaging, cartoon branding, questionable ingredients, and a race to capture market share before anyone asks too many questions.
Maybe this outcome was inevitable. Human beings have always searched for relief, connection, meaning, and altered states of consciousness. If legal pathways don’t exist, alternative markets almost always emerge to fill the gap.
The real question isn’t whether people are interested in psychedelics. Clearly, they are. The question is whether we’ll learn anything from the cannabis experience.
Can we create systems that prioritize safety without crushing access? Can we respect traditional uses while acknowledging modern realities? Can we avoid pricing ordinary people out of the very therapies they helped normalize?
Curiosity isn’t going away.
Neither is the market.
Whether you’re excited by the psychedelic renaissance or skeptical of the latest gummies and vape carts hitting shelves, one thing seems certain: the future arrived before the rulebook did.
And if history has taught us anything, it’s that catching up after the fact is a lot messier than getting it right from the beginning.
Dabbin-Dad Newsroom
